Avidity Biosciences, Inc.
Clinical trials sponsored by Avidity Biosciences, Inc., explained in plain language.
-
New hope for duchenne: targeted therapy now available for eligible patients
Disease control AVAILABLEThis program provides access to an experimental drug, AOC 1044, for people with Duchenne muscular dystrophy (DMD) whose genetic mutation can be treated by skipping exon 44. The goal is to help control the disease by allowing the body to produce a shorter but still functional dyst…
Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated May 17, 2026 06:34 UTC
-
New drug trial hopes to slow muscle loss in FSHD
Disease control Recruiting nowThis study tests an experimental drug called AOC 1020 in 200 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic disease that causes progressive muscle weakness. Participants receive either the drug or a placebo by IV every few weeks. The goal is to see if the dr…
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated May 11, 2026 20:46 UTC